We reviewed randomized stage II/III trials looking at initial- or second-line endocrine therapy simply because monotherapy or in conjunction with targeted therapies for treatment of postmenopausal sufferers with hormone receptor-positive advanced breasts cancer tumor. as monotherapy, or in conjunction with everolimus, palbociclib or ribociclib, had been evaluated. First-line monotherapy with anastrozole, fulvestrant 500 mg or… Continue reading We reviewed randomized stage II/III trials looking at initial- or second-line